Getting semaglutide covered by insurance is possible, but the path depends on why you’re taking it, what type of insurance you have, and whether your plan explicitly covers weight management drugs. The brand-name versions (Ozempic and Rybelsus for type 2 diabetes, Wegovy for weight loss and cardiovascular risk reduction) each have different coverage rules, and your out-of-pocket cost can range from as little as $25 per month to the full list price if your plan excludes the drug entirely.
Why Your Diagnosis Matters More Than the Drug
Insurance companies don’t just approve semaglutide as a blanket medication. They approve it for a specific FDA-approved use, and the diagnosis your doctor submits determines which coverage pathway applies. Ozempic and Rybelsus are approved for adults with type 2 diabetes to improve blood sugar control and reduce the risk of heart attack, stroke, and cardiovascular death. Wegovy is approved separately for weight management and cardiovascular risk reduction in people with established heart disease who also have obesity or are overweight.
If you have type 2 diabetes, your chances of getting coverage are significantly higher. Most commercial and government plans include diabetes medications on their formularies. If you’re seeking semaglutide purely for weight loss, the picture gets more complicated. Many employer-sponsored plans exclude weight loss drugs entirely, and no federal law requires them to cover these medications. A 2026 federal appeals court ruling upheld an insurer’s right to exclude weight loss drug coverage without it being considered disability discrimination.
BMI and Comorbidity Thresholds
When insurance does cover semaglutide for weight management, you’ll need to meet specific clinical thresholds. The standard criteria used by most plans look like this:
- BMI of 30 or higher with no additional conditions required
- BMI of 27 to 29.9 with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol
Your doctor will need to document your BMI at the time of prescribing along with any qualifying conditions. This documentation becomes part of the prior authorization request, so make sure your weight and relevant lab work are recorded at a recent office visit before submitting.
Step Therapy: Drugs You May Need to Try First
Many plans won’t approve semaglutide as a first-line treatment, especially for diabetes. Instead, they use “step therapy,” requiring you to try less expensive medications first and show they didn’t work well enough. For type 2 diabetes, the typical progression starts with metformin, then moves to an older drug class like a sulfonylurea or pioglitazone. After that, you may need to try another category of medication (such as an SGLT-2 inhibitor or DPP-4 inhibitor) before your plan will approve a GLP-1 like semaglutide.
This process can take months if you’re starting from scratch. If you’ve already tried and failed these medications in the past, even with a different doctor, make sure those records are available. Your prescriber can document prior treatment failures to skip steps you’ve already completed. The key phrase insurers look for is “inadequate response” or “intolerance due to side effects,” so be specific with your doctor about what happened with each previous medication.
How Prior Authorization Works
Almost every insurance plan requires prior authorization for semaglutide, meaning your doctor’s office submits a request to the insurer before the pharmacy can fill it. This request includes your diagnosis, BMI, relevant lab results, a list of medications you’ve already tried, and any weight-related conditions that have improved or worsened.
The turnaround time varies. Some plans respond within 24 to 72 hours, while others take up to two weeks. If your doctor’s office has experience with these requests, they’ll know what documentation your specific insurer expects. If the prior authorization is denied, you have the right to appeal.
What to Do When You’re Denied
Denials are common, but they’re not the end of the road. The most effective tool in an appeal is a letter of medical necessity from your doctor. This letter should include your highest recorded weight (excluding pregnancy), your current weight, a list of health conditions that semaglutide is treating or would treat, specific reasons why alternative medications won’t work for you (side effects, lack of effectiveness, or medical contraindications), and the start and stop dates of any GLP-1 medications you’ve tried before.
Conditions that strengthen an appeal include documented improvements or expected improvements in diabetes, prediabetes, cardiovascular disease, high cholesterol, high blood pressure, fatty liver disease, obstructive sleep apnea, and polycystic ovarian syndrome. The more specific your doctor can be about how obesity is affecting your other conditions, the stronger the case. Generic letters get denied. Detailed, patient-specific letters with clinical data get approved at much higher rates.
You typically get two levels of internal appeal before you can request an independent external review. Each level requires a new submission, so keep copies of everything.
Medicare Coverage
Medicare’s rules have historically been restrictive for weight loss drugs, but the landscape is shifting. If you have Medicare and established cardiovascular disease, Wegovy may already be coverable under standard Part D for cardiovascular risk reduction. Your Part D plan’s formulary determines whether it’s included and at what tier.
For weight management specifically, CMS is launching a short-term demonstration program called the Medicare GLP-1 Bridge, running from July 1, 2026 through December 31, 2027. This program will cover Wegovy and certain other GLP-1 drugs for eligible beneficiaries who meet these criteria:
- BMI of 35 or higher at the time treatment starts
- BMI of 30 or higher with a diagnosis of heart failure with preserved ejection fraction, uncontrolled high blood pressure (despite already taking two blood pressure medications), or chronic kidney disease stage 3a or above
- BMI of 27 or higher with a history of heart attack, stroke, symptomatic peripheral artery disease, or prediabetes
These thresholds are stricter than what most commercial plans require. If you’re on Medicare and your BMI is between 27 and 30, you’ll need one of those specific diagnoses to qualify under the bridge program.
Employer Plans and Coverage Gaps
Among large employers with 5,000 or more employees, 66% reported that covering GLP-1 drugs for weight loss had a significant impact on their prescription drug spending. The result: many employers have tightened requirements dramatically or dropped weight loss drug coverage altogether. Some now restrict semaglutide coverage only to patients with a formal diabetes diagnosis, removing access for weight management entirely.
Before your doctor submits a prior authorization, call the number on the back of your insurance card and ask two direct questions: Does my plan cover semaglutide (or the specific brand your doctor prescribed)? And does my plan have an exclusion for weight loss medications? If the answer to the second question is yes, the prior authorization will be denied regardless of your BMI or health conditions. Knowing this upfront saves weeks of waiting.
If your employer plan excludes the drug, your options narrow to paying out of pocket, using manufacturer savings programs, or asking your employer’s benefits team to reconsider the exclusion during the next plan year. Some employers have added coverage after employees made the case that treating obesity reduces costs for related conditions like diabetes and joint replacements.
Manufacturer Savings Cards
Novo Nordisk offers a savings program for Wegovy that can reduce your copay to as little as $25 per month if you have eligible commercial insurance. The program covers up to $100 per month in savings. This card works alongside your insurance, not as a replacement for it. You still need an active, approved prescription through your plan.
These savings cards don’t work with government insurance (Medicare, Medicaid, Tricare) and they have expiration dates that change periodically. The current self-pay offers for lower Wegovy doses are available through mid-2026, but these are limited to the introductory dose strengths and aren’t a long-term solution.
Steps to Take Right Now
Start by checking your plan’s formulary online or calling your insurer. Look for semaglutide by brand name (Ozempic, Rybelsus, or Wegovy) and note which tier it falls on, since higher tiers mean higher copays. Ask specifically about weight loss drug exclusions if that’s your intended use.
Next, schedule a visit with your doctor and make sure your weight, BMI, blood pressure, and any relevant lab work are documented in that visit’s notes. Bring a list of every weight loss or diabetes medication you’ve tried in the past, including approximate dates and why you stopped. This gives your doctor everything needed to submit a strong prior authorization on the first attempt. If your plan requires step therapy and you haven’t tried the prerequisite medications, discuss a timeline with your doctor for completing those steps efficiently rather than waiting months between each change.